Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus.
The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors.
It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 25 | -13.10 Decreased by -5.85 K% | -3.67 Decreased by -256.95% |
| Nov 6, 24 | -3.07 Decreased by -648.78% | -2.16 Decreased by -42.13% |
| Aug 6, 24 | 0.03 Increased by +106.98% | -0.16 Increased by +118.75% |
| May 7, 24 | -0.22 Increased by +58.49% | -0.19 Decreased by -15.79% |
| Mar 12, 24 | -0.22 Increased by +56.86% | -0.27 Increased by +18.52% |
| Nov 2, 23 | -0.41 Increased by +6.82% | -0.47 Increased by +12.77% |
| Aug 3, 23 | -0.43 Increased by +8.51% | -0.49 Increased by +12.24% |
| May 4, 23 | -0.53 Increased by +36.90% | -0.48 Decreased by -10.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 629.00 K Decreased by -76.54% | -82.15 M Decreased by -194.53% | Decreased by -13.06 K% Decreased by -1.16 K% |
| Sep 30, 24 | 1.27 M Decreased by -60.82% | -19.26 M Decreased by -6.75% | Decreased by -1.52 K% Decreased by -172.47% |
| Jun 30, 24 | 1.06 M Decreased by -84.59% | 5.06 M Increased by +126.93% | Increased by +477.00% Increased by +274.80% |
| Mar 31, 24 | 986.00 K Decreased by -63.79% | -34.86 M Decreased by -51.88% | Decreased by -3.54 K% Decreased by -319.43% |
| Dec 31, 23 | 2.68 M Decreased by -24.20% | -27.89 M Decreased by -27.44% | Decreased by -1.04 K% Decreased by -68.13% |
| Sep 30, 23 | 3.24 M Decreased by -21.12% | -18.04 M Increased by +3.11% | Decreased by -556.99% Decreased by -22.82% |
| Jun 30, 23 | 6.89 M Increased by +86.46% | -18.79 M Increased by +5.69% | Decreased by -272.89% Increased by +49.42% |
| Mar 31, 23 | 2.72 M Increased by +5.91% | -22.95 M Increased by +35.55% | Decreased by -843.00% Increased by +39.14% |